Material Safety Data Sheet Section 1. Identification of the substance Product Name: 5-Amino-3-methylisoxazole-4-carbonitrile Synonyms: 5-Amino-4-cyano-3-methylisoxazole Section 2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section 3. Composition/information on ingredients. Ingredient name: 5-Amino-3-methylisoxazole-4-carbonitrile CAS number: 35261-01-9 Section 4. First aid measures Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section 5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section 6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution: Wear approved mask/respirator Hand precaution: Wear suitable gloves/gauntlets Skin protection: Wear suitable protective clothing Eye protection: Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section 7. Handling and storage Handling: This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels. Storage: Section 8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section 9. Physical and chemical properties Appearance: Not specified Boiling point: No data No data Melting point: Flash point: No data Density: No data Molecular formula: C5H5N3O Molecular weight: 123.1 Section 10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides. Section 11. Toxicological information No data. Section 12. Ecological information No data. Section 13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section 14. Transportation information Non-harzardous for air and ground transportation. Section 15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313.
[EN] HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF [FR] COMPOSÉ D'ACIDE HYDROXAMIQUE AYANT UNE ACTIVITÉ INHIBITRICE DE L'ENPP1 ET SON UTILISATION [ZH] 具有ENPP1抑制活性的异羟基肟酸类化合物及其用途
[EN] HCV INHIBITING BI-CYCLIC PYRIMIDINES<br/>[FR] PYRIMIDINES BICYCLIQUES INHIBANT LE VHC
申请人:TIBOTEC PHARM LTD
公开号:WO2006035061A1
公开(公告)日:2006-04-06
The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinat ions of the present bi-cyclic pyrimidines with other anti-HCV agents.
Bicyclicpyrimidones and their use to treat diseases
申请人:——
公开号:US20040242596A1
公开(公告)日:2004-12-02
The present invention is directed to dihydropyrimidones having formula I or II and methods of using them to induce mitotic arrest, thereby making them useful as anti-cancer agents and other diseases that can be treated by inducing mitotic arrest.
1
4-Methoxy-1,2,3-benzotriazine, like the 4-methyl and 4-phenyl compounds, forms the 2-oxide on N-oxidation; this is hydrolysed to the acidic 3,4-dihydro-4-oxo-1,2,3-benzotriazine 2-oxide, which is N-methylated by diazomethane at the 3-position. The 4-methoxy 2-oxide was converted into 4-amino- and 4-hydrazine-derivatives. 5-Amino-3-methylisoxazole-2-carbonitrile forms 3,4-dihydro-5-methyl-4-oxoisoxazolo[5
A Ready One-pot Preparation for Pteridine and Isoxazolo[3,4-d]pyrimidine Derivatives
作者:José Ma Quintela、Carlos Peinador、Mar誕 J. Moreira、Rosa Toba、Marcos Chas
DOI:10.3987/com-06-10686
日期:——
Several new substituted pteridines and isoxazolo[5,4-d]pyrimidines are easily obtained by an efficient one-pot procedure from the reaction of N,N-dimethyldichloromethyleniminium chloride (phosgeniminium chloride) with the precursors β-enaminonitriles 2-amino-3-cyano-5-phenylpyrazine (5) and 5-amino-4-cyano-3-methylisoxazole (1), respectively.